Focused On-demand Library for Large ribosomal subunit protein uL14m

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q6P1L8

UPID:

RM14_HUMAN

Alternative names:

39S ribosomal protein L14, mitochondrial; 39S ribosomal protein L32, mitochondrial

Alternative UPACC:

Q6P1L8; B2R575; Q96Q72

Background:

The Large ribosomal subunit protein uL14m, also known as 39S ribosomal protein L14 and L32, mitochondrial, plays a crucial role in ribosome assembly. It forms part of 2 intersubunit bridges, essential for the ribosome's structure and function. Its interaction with MALSU1 inhibits bridge formation, thus repressing translation, which is a probable mechanism for controlling protein synthesis.

Therapeutic significance:

Understanding the role of Large ribosomal subunit protein uL14m could open doors to potential therapeutic strategies. Its involvement in the fundamental process of translation and ribosome assembly highlights its potential as a target for developing treatments that require modulation of protein synthesis.